Skip to main content
. 2015 Oct 20;6:1146. doi: 10.3389/fmicb.2015.01146

Table 3.

Frequency of antimicrobial non-susceptibility in three major epidemic lineages in the 69 CNSAb isolates.

% Non-susceptibility to CLSI antimicrobial groupsa
ICb (No.) A
B
O
IPM MEM CAZ SAM AMK TOB GEN CIP PIP TZP FEP MIN TET TGC LVX SXT CST RIF
IC1 (13) 100 100 100 85 92 62 92 100 100 100 100 48 46 9 100 100 0 100
IC2 (25) 100 92 88 48 84 76 88 88 96 92 96 19 32 5 88 96 0 92
V (31) 100 100 100 61 84 61 100 97 100 97 100 25 39 24 97 100 0 97
Total (69) 100 97 96 65 86 66 93 95 99 96 97 31 39 13 95 99 0 97

aConsiderations in the assignment of agents to Groups A, B, and C include clinical efficacy, prevalence of resistance, minimizing emergence of resistance, cost, FDA clinical indications for usage, and current consensus recommendations for first-choice and alternative drugs. Group A are considered appropriate for inclusion in a routine, primary testing panel, as well as for routine reporting of results for the specific organism. Group B comprises agents that may warrant primary testing. Group O (Other) includes agents that have a clinical indication for the organism. Escherichia coli ATCC25922 and Pseudomonas aeruginosa ATCC27853 were used for quality control of antimicrobial susceptibility testing and included in each run.

bIC, international clonal lineage; V, IC variants; AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colisitin; FEP, cefepime; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; MIN, minocycline; PIP, piperacillin; RIF, rifampicin; SAM, ampicillin-sulbactam; SXT, trimethoprim- sulfamethoxazole; TET, tetracycline; TGC, tigecycline; TOB, tobramicin; TZP, piperacillin-tazobactam.